An audit at ICON concluded the company overstated revenue by $65.3 million in 2023 and $92.7 million in 2024, according to the prompt text. The disclosure also referenced cash-raising activity including Secretome and Psilera, but the audit finding is the key governance trigger for the CRO sector. For biotech buyers and sponsors, audit outcomes matter because CRO billing integrity affects contracting, budgeting, and reconciliation of performance-linked invoices. The case also raises the bar for CRO internal controls as sponsors continue to increase digital tooling adoption and demand greater transparency around operational metrics. The update is likely to influence diligence and procurement scrutiny across clinical research services, particularly for programs tied to complex modality pipelines and tight timelines.